

# **Drug Interactions in Primary Healthcare in the George area, South Africa: A Cross-Sectional Study**

By  
Paul Alfred Kapp

*Thesis presented in partial fulfilment of the requirements for the degree  
Master of Family Medicine at the University of Stellenbosch*



Supervisor: Dr Andre Klop  
Co-supervisor: Dr Louis Jenkins  
Faculty of Health Sciences  
Division of Family Medicine

July 2011

### **Declaration**

By submitting this thesis electronically, I declare that the entirety of the work contained therein is my own, original work, and that I am the owner of the copyright thereof (unless to the extent explicitly otherwise stated) and that I have not previously in its entirety or in part submitted it for obtaining any qualification.

Date: 10 July 2011

Dr Paul Alfred Kapp

## Abstract

**Aim:** To investigate the prevalence of potential drug-drug interactions in primary healthcare clinics in the George subdistrict. Objectives included: To investigate and quantify the following risk factors: patient age, poly-pharmacy, gender, multiple prescribers and recorded diagnoses, as well as to identify and quantify the drugs involved, including the level of any drug-drug interactions.

**Design:** A descriptive cross-sectional study was performed at four primary healthcare clinics in George from 400 randomly selected patients' files for patients who attended these clinics from 1 February to 30 April 2010. Demographics, recorded diagnoses and all concurrently prescribed drugs were recorded and analysed. The level of drug-drug interaction was classified using the Operational Classification of drug-drug interactions designed by Hansten and Horn.

**Results:** The prevalence for moderate interactions was 42%, severe interactions 5.25% and contraindicated combinations was 0.5%. The most common drugs involved in potential drug interactions were: enalapril, aspirin, ibuprofen, furosemide and fluoxetine. The most common drugs involved in potentially severe interactions were: warfarin, aspirin, fluoxetine, tramadol and allopurinol. Two contraindicated combinations were found: verapamil plus simvastatin, and hyoscine butyl bromide with oral potassium chloride. Increasing age and poly-pharmacy were associated with an increased risk for potential drug-drug interactions. Input from the regional hospital specialist departments greatly increased the risk of being prescribed a potential drug-drug interaction. Eighty one per cent (17/21) of severe interactions were from this group. The majority of patients in the sample were female (65.5%) but there was no differences in the percentage of drug interactions between males (43.4%) and females (43.1%).

**Conclusion:** Potential drug-drug interactions are commonly prescribed in primary healthcare clinics in the George subdistrict. Drug interactions are predictable and preventable. It would seem prudent to put into place a method of reducing the risk. Further research is needed to identify effective interventions suitable for resource constrained centres. The risk factors identified in this study may assist in designing such an intervention.

## Introduction

In developed countries, drug-drug interactions (DDIs) are a recognised source of morbidity and mortality<sup>1</sup>. This has led to innovative means of addressing the issue including computerised methods to detect potential interactions<sup>2</sup>. In developing countries like South Africa, little work has been done to determine the extent of the problem and even less to reduce the risk. In a country where a significant percentage of the population is on anti-retrovirals, anti-tuberculous drugs or medications for chronic diseases it would seem prudent to investigate and develop practical methods of reducing this risk.

In the George subdistrict, primary healthcare practitioners saw and treated an average of 3450 patients per day in four primary healthcare clinics during February to April 2010. Many of these patients have complex conditions and are managed by a number of doctors, including specialists from secondary and tertiary hospitals. The resultant discontinuity of multiple doctors and clinical nurse practitioners servicing these patients increases the potential for DDIs. In addition, large numbers of patients are elderly, suffer from chronic diseases and receive a multitude of medications.

It would appear therefore that the likelihood of significant numbers of DDIs occurring in this context should be similar to that of other South African primary healthcare clinics and be at least as high as in countries where the problem has been researched<sup>1-19, 21-41</sup>. Adverse clinical effects due to DDIs are often not recognised by health care practitioners and further medications are added to treat these signs and symptoms. Clinically, it may be difficult to decide between drug interactions, adverse reactions, side effects or deterioration of the patient's condition as the cause of the presenting clinical picture<sup>3</sup>. Consider Mr H who presents at an emergency centre with generalised muscle pains after a day's gardening. The medical officer examines him and, finding nothing of significance prescribes diclofenac and sends him home. He presents two days later in severe pain with apparent haematuria and renal failure and is admitted. During admission it is discovered that the haematuria is in fact myoglobinuria secondary to rhabdomyolysis. Mr H has hypertensive heart disease and is on a number of drugs including simvastatin, prescribed by his physician. He developed tinea unguium of the toenails for which he was prescribed itraconazole by his general practitioner (GP) resulting in toxic levels of simvastatin and rhabdomyolysis. The potentially nephrotoxic diclofenac increased the likelihood of Mr H developing renal failure.

This and similar cases led to the question, “What is the prevalence of potential drug-drug interactions as reflected in the prescriptions of patients from primary healthcare clinics in the George subdistrict, which drugs are involved and what are the associated risk factors?

### Literature Review

A Medline search using the terms “prevalence AND drug-drug interactions AND primary healthcare” returned 121 articles of which 37 were relevant. Other databases were searched but were not contributory. Many studies were found dealing with adverse drug reactions (ADRs) in elderly and hospitalised patients<sup>1,4</sup> but few studies addressed ADRs in primary healthcare (PHC).<sup>2</sup> DDIs are a subset of ADRs that are preventable, but hardly any studies dealt with DDIs in PHC and only two of these studies came from developing countries, viz. Mexico and South Africa.<sup>7,20</sup>

The drugs involved varied from country to country and even from region to region, making it impossible to extrapolate data from other studies to the South African context. However warfarin was commonly implicated in severe interactions.<sup>9, 12, 15, 19</sup>. A systematic review of the world-wide literature found that the top four drug classes comprised 51% of interactions<sup>18</sup>.

- Antiplatelets (16%)
- Diuretics (16%)
- NSAIDs \* (11%)
- Anticoagulants (8%)

Risk factors for DDIs from the literature were:

- Polypharmacy<sup>1, 4</sup>
- Extremes of age (very young<sup>5</sup> or elderly<sup>9</sup>)
- Multiple co-morbidities<sup>1,4</sup> especially cardiovascular disease<sup>7</sup>
- Greater number of prescribing physicians<sup>21</sup>

The prevalence of DDIs in the international literature ranges from 0.7% to 80%. Adverse drug reactions are the 6<sup>th</sup> leading cause of in-hospital mortality in the United States<sup>4</sup>. In the United Kingdom 3% of children on anti-epileptic medication were prescribed additional medications having potentially severe DDIs.<sup>5</sup> Between 1964 and 2000 sixty-five childhood deaths resulted from drug-interactions with anti-epileptic drugs<sup>5</sup>. In 2007 in Denmark, with its highly computerised healthcare system, 94.3% of prescriptions had one or more

---

\* Non-steroidal anti-inflammatory drugs

inappropriate ratings in terms of the Medication Appropriate Index<sup>6</sup>. Only 0.7% of these were due to drug-drug-interactions<sup>6</sup>. In an earlier (2003) study in Denmark, Bjerrum found that 4% of hospital admissions were due to drug interactions<sup>8</sup>. While in 1993 Linnarson<sup>3</sup> found a 12% prevalence of Potential-DDIs (P-DDIs) in primary healthcare in Denmark. (The decrease in prevalence over time is possibly due to the increased use of computer-assisted decision making.)

In contrast, a study of prescriptions issued to patients over 50 years of age in Family Medicine clinics in Mexico City revealed that 80% of scripts had one or more DDIs and 3.8% had level 1 (contraindicated) drug interactions<sup>7</sup>. However, these studies are difficult to compare. They differ in methodology, which DDIs are included, and what denominator is used to calculate prevalence and incidence. The only South African study listed in PubMed deals with DDIs and HIV drugs in a medical-aid database<sup>20</sup>. Of 43482 prescriptions analysed, 18035 P-DDIs were found. This study however excluded all anti-tuberculous medications. No studies were found in PubMed or Medline dealing with the prevalence of DDIs in primary healthcare in South Africa (23 May 2011).

#### **Aim:**

To investigate potential drug-drug interactions in the prescriptions issued at primary healthcare clinics in the George subdistrict.

#### **Objectives:**

1. To determine the prevalence of potential DDIs in prescriptions issued at four PHC clinics in the George subdistrict.
2. To determine the most common drugs involved.
3. To grade the levels of drug-drug interactions according to the Operational Classification of drug interactions (ORCA)<sup>12, 13</sup>.
4. To establish any association between specific chronic diseases and prescriptions containing P-DDIs.
5. To determine the effect that specialist prescribers from George Hospital have on the prevalence of DDIs in the scripts of patients followed up in PHC clinics.

## Methodology

Ethics approval was obtained from the University of Stellenbosch Ethics Committee, reference N09/08/203<sup>†</sup>. The main ethical consideration was protecting patient privacy. This was dealt with by using a de-identified database and password protection of sensitive data. A waiver of informed consent was granted by the ethics committee. Permission for the study was obtained from the Western Cape Department of Health, reference 19/18/RP114/2009<sup>‡</sup>. The study sites were four primary health care clinics in the George subdistrict of Western Cape:

- Thembalethu
- Sentrum
- Pacaltsdorp
- Conville

## Design:

A cross-sectional study of the drugs prescribed to patients in PHC clinics was used to determine the prevalence of P-DDIs and to evaluate associations. The study population was the patients making use of PHC facilities at the above clinics from 1<sup>st</sup> February to 30<sup>th</sup> April 2010. No other inclusion or exclusion criteria were applied. Simple random sampling was used. The number of patients who attended the clinics from 1 February to 30 April 2010 was obtained. Random numbers were generated by computer equivalent to the sample size (n=400) within these totals. These random numbers were used to draw the corresponding files. The sample size needed to estimate a proportion with a 95% Confidence Interval (CI) and a precision of 5% ( $C_p = 5\%$ ) was determined to be at least 385 scripts. Four hundred scripts were analysed.

---

<sup>†</sup> See Appendix 1

<sup>‡</sup> See Appendix 2

## Method of Data Collection:

Data was collected from the prescriptions from patients' files and recorded in a password protected database. The variables included age, sex, all drugs prescribed concurrently during the period in question and chronic diseases recorded in the files. The data was transferred into a de-identified spread-sheet to protect the privacy of patients and prescribers. The drug lists were analysed using Medscape's drug interaction checker for drug interactions ([www.medscape.com](http://www.medscape.com)) and verified using ePocrates® software as a form of concurrent convergent validity. These are valid and reliable instruments to detect DDIs.<sup>26, 32</sup> ePocrates® compares favourably with drug compendia for accuracy<sup>27</sup>. The evidence for an interaction was obtained from Medscape and recorded in a separate file linked to the spreadsheet. Each interaction was classified according to the ORCA classification<sup>12, 13</sup>. Data from each site was collected individually allowing analysis of this data separately and as part of the total. Rigour was ensured by linking a range of validity and reliability checks in the database and spreadsheet. In order to distinguish trivial from significant effects the ORCA, classification levels 1 to 3 were identified (Table 1) and recorded as contraindicated, severe, or moderate interactions.


**Table 1 Hansten and Horn's Operational Classification of drug interactions (ORCA). Adapted from references 10,12,16,39**

Level	Management	Examples
1 (Contraindicated)	Avoid combination because the risk always outweighs the benefit	nitroglycerin - sildenafil
2 (Severe)	Usually avoid the combination  -alternatives are available for one or both drugs	simvastatin and amiodarone
3 (Moderate)	-avoid unless the benefit outweighs the risk of the DDI  Minimise risk  -consider alternatives that may be less likely to cause DDI  -circumvent the interaction by taking precautionary measures	warfarin and rifampicin
4	-monitor for early detection of the DDI	efavirenz and TMX/SMX
5	No special precautions needed as risk of adverse effect is small  Ignore as DDI does not occur per existing evidence	paracetamol and codeine

## Statistical Analysis

The data was analysed by the researcher with support from the Centre for Statistical Consultation (CSC), Stellenbosch University, using STATISTICA version 10.0 [www.statsoft.com](http://www.statsoft.com). Summary statistics were conducted using frequency tables, histograms, means and standard deviations. Comparisons of different sub groups were done using the Chi-square test for comparing nominal responses and one-way ANOVA for comparing continuous responses. Analysis was done to determine associations between chronic disease conditions and DDIs. Similarly, the relationship between patients' age and DDIs and between the numbers of drugs prescribed and DDIs were determined. The effect of prescribers from the George hospital specialist departments was also examined. A significance level of 5% was used for all hypotheses tested.

Patients attending research site clinics during the period February to April 2010 n = 207468  
Randomly selected 400 files



## Results

The following tables and figures that present the results deal firstly with the prevalence of P-DDIs. Thereafter, the drugs that were involved are outlined and the findings as regards severe interactions as well as contra-indicated combinations are presented. Finally, the different associations that were investigated are detailed.

There were 2265 drugs prescribed in the 400 scripts analysed, (5.66 drugs per script). Using Medscape's interaction checker, 173 scripts (43.25%) were found to have at least one potential-drug-to-drug interaction. (Table 2)

**Table 2 Number of prescriptions containing P-DDIs at the four PHC clinics. The percentage of the scripts containing a DDI is in brackets.**

Site	Scripts analysed	Moderate Interactions	Severe Interactions	Contraindicated Combinations
Thembalethu	200	81 (40.5%)	5 (2.5%)	1 (0.5%)
Conville	65	24 (36.9%)	3 (4.6%)	0 (0.0%)
Sentrum	65	35 (53.9%)	9 (13.9%)	1 (1.5%)
Pacaltsdorp	70	28 (40.0%)	4 (5.7%)	0 (0.0%)
<b>Totals</b>	<b>400</b>	<b>168 (42.0%)</b>	<b>21 (5.3%)</b>	<b>2 (0.5%)</b>
<b>Statistica</b>		Chi-square(df=3)=4.68, p=.99660	Chi-square(df=3)=10.63, p=.01392	Chi-square(df=3)=2.26, p=.52055

Overall 366 potential-drug-interactions were present, an average of 0.92 potential-interactions per script. (Table 3)

**Table 3 Breakdown of the total P-DDIs found**

Total potential drug interactions	366
No. of moderate interactions	336
No. of severe interactions	28
No. of contraindicated interactions	2

Table 4 presents the fifteen drugs that were most commonly prescribed in descending order of frequency.

**Table 4 Top fifteen drugs prescribed**

<i>Ranking</i>	<i>Drugs</i>	<i>Number of times prescribed</i>
1	Paracetamol	162
2	Aspirin	131
3	Enalapril	124
4	Hydrochlorothiazide	109
5	Amlodipine	99
6	Simvastatin	86
7	Ung methyl salicylate	77
8	Ibuprofen	71
9	Amoxicillin	63
10	Metformin	57
11	Atenolol	49
12	Amitriptyline	48
13	Vit Bco	45
14	Furosemide	40
15	Chlorpheniramine	37

**Figure 1 Top ten causes of P-DDIs and the number of times they were prescribed**




Figure 1 presents the drugs that were most commonly involved in potential-drug-interactions. Some drugs were involved in more DDIs than the number of times that they were prescribed. For example, digoxin ranked 14 as a cause of P-DDIs. It was prescribed only four times but was involved in ten P-DDIs. Furosemide, spironolactone, simvastatin and metoclopramide were the drugs implicated in moderate interactions with digoxin. Because these drugs are often prescribed together, it is easy to understand how digoxin had a 250% risk of being involved in a P-DDI if it was prescribed. The most common interaction occurred between enalapril and aspirin (Level 3), with 86 occurrences.

Table 5 represents the drugs that were involved in P-DDIs more often than they were prescribed. Many of these were introduced by specialist departments from the local regional hospital. The final column represents the number of DDIs divided by the number of times the drug was prescribed expressed as a percentage to indicate risk.

**Table 5 Drugs at highest risk of being involved in an interaction if prescribed.**

<u>Ranking</u>	<u>Drugs Most likely to cause DDIs</u>	<u>Number of times prescribed</u>	<u>Number of times involved in</u>	<u>Percentage of times involved in a DDI vs. times prescribed</u>
1	Digoxin	4	10	250.0%
2	Amphotericin B loz	1	2	200.0%
3	Lamotrigine	1	2	200.0%
4	Venlafaxine	1	2	200.0%
5	Warfarin	12	21	175.0%
6	Propranolol	2	3	150.0%
7	Telmisartan	2	3	150.0%
8	Fluoxetine	19	27	142.1%
9	Losartan	3	4	133.3%
10	Enalapril	124	161	129.8%

Table 6 contains the top twenty prescribed drugs that were not involved in a P-DDI, (except amlodipine which was prescribed 99 times but was only implicated in a single P-DDI with Titralac® (calcium carbonate)).

**Table 6 Drugs least likely to cause DDIs**

Amlodipine	Cefixime	Hydralazine
Ung methyl salicylate	Doxazosin Cardura XL	Stavudine
Amoxicillin	Efavirenz	Normal saline nose drops
Vit Bco	Medroxyprogesterone acetate	Promethazine
Chlorpheniramine	Omeprazole	Ipratropium bromide
Codeine	Vidaylin / multivitamins	Orphenadrine
Lamivudine	Sorol citrate powder	

## Severe Interactions


Twenty-one prescriptions contained a total of 28 level 2 (severe) P-DDIs. These were due to 15 different interactions. (Table 7)

**Table 7 Severe interactions**

<i>Severe Drug Interactions</i>	<i>Occurrences</i>
<i>Warfarin ↔ Aspirin</i>	<i>6(21.43%)</i>
<i>Fluoxetine ↔ Clonazepam</i>	<i>3(10.71%)</i>
<i>Tramadol ↔ Amitriptyline</i>	<i>3(10.71%)</i>
<i>Warfarin ↔ Allopurinol</i>	<i>3(10.71%)</i>
<i>Ferrous sulphate ↔ Doxycycline</i>	<i>2(7.14%)</i>
<i>Tramadol ↔ Fluoxetine</i>	<i>2(7.14%)</i>
<i>Allopurinol ↔ Theophyllin</i>	<i>1(3.57%)</i>
<i>Amphotericin B ↔ Anusol</i>	<i>1(3.57%)</i>
<i>Amphotericin B ↔ Budesonide</i>	<i>1(3.57%)</i>
<i>Ferrous sulphate ↔ Ciprofloxacin</i>	<i>1(3.57%)</i>
<i>Lamotrigine ↔ Valproic Acid</i>	<i>1(3.57%)</i>
<i>Methotrexate ↔ Diclofenac</i>	<i>1(3.57%)</i>
<i>Quinine ↔ Rifampicin</i>	<i>1(3.57%)</i>
<i>Spiromolactone ↔ Potassium chloride</i>	<i>1(3.57%)</i>
<i>Warfarin ↔ Metronidazole</i>	<i>1(3.57%)</i>

Warfarin was involved in ten and aspirin in six severe P-DDIs. (Figure 2)

**Figure 2 Drugs Involved in Severe Interactions**



## Contraindicated Combinations

Two instances of contraindicated combinations were found. Hyoscine butyl bromide and oral potassium chloride were prescribed together at Thembalethu while simvastatin with verapamil were prescribed at Sentrum clinic.

## The Associations Investigated

### 1. Diseases associated with DDIs

The top four diagnoses recorded in the files were hypertension, type-2-diabetes, Human Immunodeficiency Virus infection (HIV) and osteoarthritis. These were examined to determine the percentage of scripts with a P-DDI. The percentage of scripts containing a severe P-DDI was also determined. (Table 8)

Table 8 Chronic diseases and P-DDIs (Total number of scripts = 400)

Disease	Number of patients diagnosed with	Percentage of scripts containing a potential DDI	Percentage of scripts with a potentially severe DDI	Average number of drugs per script
Hypertension	150 (37.5%)	72.7%	6.7%	7.2
Type 2 Diabetes	58 (14.5%)	81.0%	12.1%	8.3
HIV	39 (9.8%)	38.5%	2.6%	7.7
Osteoarthritis	32 (8.0%)	81.3%	6.3%	8.9

### 2. The effect of prescribers from George hospital

A total of 109 (27%) of the prescriptions had evidence of input from the George provincial




Figure 3 P-DDIs with input from George hospital compared to P-DDIs with input from PHC staff only (Chi-squared(df=2)=16.18, p=0.00031)

came from this group of patients compared to 19% (4/21) that only had input from the PHC staff.

In the group where the drugs originated from George hospital, 63.3% (69/109) of the scripts had at least one moderate interaction with a corresponding figure of 34% (99/291) for the group where all the drugs originated from the PHC clinics only. (Chi-square (df=1) =27.77, p<0.001).

regional hospital (GH) specialist departments. Of the 173 prescriptions that contained at least one DDI, 41% had input from GH.

Significantly more level 2 interactions were found in the group of scripts that were influenced by GH. Most (81%; 17/21) of the severe interactions

For contraindicated combinations, each group had one; GH = 1/109 = 0.9% and PHC = 1/191=0.5%.

### 3. Age

The mean patient age of the sample was 41 years (95% CI, 39.3-43.3). The mean age for moderate interactions was 52.6 years (95% CI, 49.8-55.3), for severe interactions, 52.5 years (95% CI, 43.8-61.2), and contraindicated combinations, 67 years (95% CI, 38.7-95.3). The mean ages do not differ significantly as tested with ANOVA where  $F (2,170) = 0.869$  with  $p=0.42 >0.05$ .


### 4. Gender

Although 65.5% of the patients in the sample were female, gender was not associated with an increased risk for P-DDIs; 43.13% of female and 43.48% of male scripts contained at least one P-DDI.

### 5. Effect of poly-pharmacy on the number of DDIs

Using the number of occurrences one can determine the average number of DDIs per script. By plotting this against the number of concurrent drugs prescribed, the tendency is for the number of DDIs to increase as the number of drugs used concurrently increases. (Figures 4 and 5).

**Figure 4: The effect of poly-pharmacy on the prevalence of DDIs: The red and blue line represents the average P-DDIs per script. The relationship is greater than linear as shown by the blue line.**






Figure 5 The dark blue area represents the percentage of patients who have at least one P-DDI for the number of drugs prescribed and the light blue is the percentage with more than one P-DDI.

## Discussion

Drug-to-drug-interactions occur when the precipitant drug alters the effect of the object drug<sup>8</sup>. Over 9000 DDIs are recognised<sup>41</sup>. Most are trivial with only a few being clinically significant<sup>9</sup>. The outcome may be harmful, even fatal, if the interaction increases toxicity or reduces the intended effect of the object drug. Other effects include gastrointestinal bleeding, renal dysfunction, electrolyte imbalances, hypertension/hypotension, and arrhythmias<sup>10</sup>. Many interactions are acceptable, for example enalapril and low dose aspirin, a moderate (level three) interaction, responsible for 86 interactions in this study. Aspirin antagonises the antihypertensive effect of ACE-inhibitors, increasing mean blood-pressure. There may be other negative effects<sup>35-37</sup>.

The prevalence of DDIs in the George subdistrict is half of that found in family medicine clinics in Mexico City, where 80.0% of the scripts of elderly patients contained P-DDIs<sup>8</sup>. However the studies are not directly comparable as they only looked at patients older than 50 years. The prevalence of *severe* interactions compares with a recent Spanish study which found the prevalence of potentially severe interactions to be 5.8% in family medicine clinics in Murcia<sup>32</sup>. The most common drugs involved were omeprazole, diazepam, warfarin, ibuprofen and calcium. In the present study warfarin and NSAIDs (aspirin, ibuprofen and diclofenac) featured prominently as did benzodiazepines. Omeprazole was found to be one of the safer drugs in this study, being prescribed thirteen times with no interactions (Table 5). The use of different interaction checkers complicates comparisons.

The increasing risk of P-DDIs with age and poly-pharmacy is well documented.<sup>7, 9, 15, 22, 23, 30</sup> However, the relatively low risk of P-DDIs in patients diagnosed with HIV was unexpected (Table 7). At 7.7 drugs per script, the average drugs-per-script was higher than the 5.7 drugs-per-script of the sample. Yet only 38.5% of scripts had moderate interactions and 2.6% of the scripts included a potentially severe-interaction. Snyder found that 77% of scripts of hospitalised HIV patients in tertiary care in Florida had medical errors of which 12% were due to DDIs<sup>34</sup>. Our study involved only ambulatory clinic patients; therefore the studies are not directly comparable. Furthermore, most were on regimen 1 of the SA national HIV guidelines, which excludes protease-inhibitors. In medical-aid patients in South Africa, Katende-Kyenda found 960 P-DDIs in 47085 prescriptions (2%) in private practice<sup>20</sup>. However, large numbers of patients were on only one or two drugs, which may explain the low prevalence of DDIs in this study.

The scripts from files where type 2 diabetes was diagnosed recorded the highest prevalence of potentially *severe* interactions (12.1%). This risk may be amplified by altered pharmacokinetics as a result of disease factors such as impaired renal function. It is probable that P-DDIs are more likely to manifest as clinical effects in these patients.

DDIs are predictable and preventable. While we need to take note of the effects of moderate interactions, these seldom cause life-threatening complications. Severe (level-two) interactions however require action to prevent harm. Level-one interactions should never be prescribed. It would seem prudent to provide some form of intervention to decrease the prevalence of level one and level two interactions. While sophisticated technological advances have reduced the risk in first world countries significantly,<sup>12, 26, 27</sup> it is unlikely that the South African public health service will embrace these technologies in the immediate future. Furthermore, electronic alerts are inconsistent, vary between products and are often ignored by prescribers and pharmacists.<sup>26, 27, 31, 40</sup>

However, simple interventions such as drug reviews and quality improvement cycles focusing on reducing P-DDIs are effective and practical solutions<sup>22</sup>. Improved communication between specialist departments and PHC clinics are also likely to have a positive effect<sup>21</sup>.

Regular medication reviews have been shown to substantially reduce the risk of DDIs and rationalise prescribing in patients with poly-pharmacy, reducing the number of medications prescribed by 20%<sup>22</sup>. Dosages modified and medications prescribed by other healthcare

providers may be discovered that the family physician was unaware of. Identifying over the counter (OTC) medications is also possible by asking the patient what other medicines (s)he uses. Regular medication reviews would create awareness amongst prescribers and patients concerning the risks of poly-pharmacy, including DDIs.

This study may help to target interventions aimed specifically at clinically important interactions by identifying the severe as well as common interactions found in typical PHC settings in South Africa. This study identified the following risk factors:

1. Drugs that are involved in P-DDIs more often than they are prescribed: Digoxin, amphotericin B, lamotrigine, venlafaxine, warfarin, propranolol and telmisartan (Table 5)
2. Drugs that commonly cause P-DDIs: Enalapril, aspirin, ibuprofen, furosemide, fluoxetine, amitriptyline and warfarin (Figure 1)
3. Drugs that cause potentially severe interactions: Warfarin, aspirin, fluoxetine, tramadol, allopurinol, amitriptyline and clonazepam (Figure 2)
4. Poly-pharmacy (more than five drugs per prescription)
5. Patients older than fifty years
6. Chronic diseases: Type 2 diabetes, hypertension or osteoarthritis
7. Involvement of specialist departments from the regional hospital.

Identifying these patients and exposing them to regular medication reviews by a family physician is likely to be beneficial and cost-effective. However, relying on memory, drug compendia or software alone is unlikely to be effective<sup>32</sup>.

### **Limitations of this study**

This study only detected *potential* interactions. Only a few people experience the effects of interactions. Therefore the clinical effects are considerably less than the figures presented here.

This study was also completely reliant on the data as recorded in the patients' files. No attempt was made to interpret or correct possible diagnostic inaccuracies.

Drug-interaction checkers vary in their sensitivity and specificity<sup>41</sup>. Where Medscape and ePocrates® had different results the results from Medscape were recorded. New drug-

The most important findings of this study are:

1. Poly-pharmacy is rife, with patients receiving up to twenty drugs per script.
2. Potential drug-drug interactions are common; 40.2% of scripts contained at least one P-DDI.
3. More than 5% of prescriptions contained a potentially severe interaction and 1 in 200 scripts have a level-one drug interaction.
4. Multiple prescribers, viz. specialist departments from a regional hospital, increased the risk of a script containing a P-DDI from PHC clinics.
5. Common diseases such as hypertension and diabetes are the diagnoses most likely to be associated with P-DDIs. Poly-pharmacy is common in HIV patients but there are fewer interactions compared to diabetes, hypertension and osteoarthritis.
6. Warfarin and aspirin are the most common cause of severe P-DDIs.
7. The elderly are more likely to be prescribed P-DDIs

interactions are continually being discovered. The results were correct as per Medscape's interaction checker on 31 January 2011.

The sample size in this study is small, making the identification of associations for contraindicated combinations (level 1 interactions) statistically insignificant. Only four PHC sites were evaluated, although these probably reflect the broader population at risk in PHC clinics in the Western Cape.

This was a cross-sectional study, thus seasonal variations, changing prescribers or changing illness profiles were not taken into account.

### Conclusion/recommendations

As in PHC clinics in other developing countries, P-DDIs are common yet unrecognised by prescribers in PHC clinics in the George subdistrict of South Africa. Although the prevalence of clinically significant events is presumed to be much lower than the figures for P-DDIs found in this study, they are still likely to be significant. By recognising this and implementing simple cost-effective mechanisms aimed at reducing DDIs, medical practitioners are likely to reduce the risk of DDIs to the patients. Electronic media are expensive and drug compendia clumsy. Identification of high risk patients and evaluating their scripts as part of a regular medicine review, as well as improving communication between prescribing physicians, is likely to improve clinical governance and result in a decrease the number of P-DDIs prescribed. The risk factors identified in this study include poly-pharmacy, elderly patients, multiple prescribers, prescription of specific drugs and type 2 diabetes, hypertension and osteoarthritis. Scheduling these patients to have a medicine review performed by a family physician and then annual follow-up reviews may be prove beneficial to the patients whilst reducing the cost of drugs.

### Acknowledgements

Dr Andre Klop assisted with the research proposal and study protocol including obtaining ethics approval and assisted with the drafting of the final manuscript.

Dr Louis Jenkins assisted with the final manuscript and provided valuable input throughout including mentoring.

Prof Daan Nel from the Centre for Statistical Consultation (CSC) assisted with the statistical analysis of the results.

My wife and children for their patience and support

Above all, God Almighty for this opportunity and His help.

## Appendix 1



19 October 2009

MAILED

Dr P Kapp  
Department of Family Medicine  
3rd Floor, Fisan building  
Stellenbosch University  
Tygerberg campus  
7505

Dear Dr Kapp

"Drug interactions in primary healthcare in the George area South Africa:A cross-sectional study."

ETHICS REFERENCE NO- N09/08/203

RE : FINAL APPROVAL

At a meeting of the Health Research Ethics Committee that was held on 2 September 2009, the above project was approved on condition that further information is submitted.

This information was supplied and the project was finally approved on 16 October 2009 for a period of one year from this date. This project is therefore now registered and you can proceed with the work.

Please quote the above-mentioned project number in ALL future correspondence

Please note that a progress report (obtainable on the website of our Division: [www.sun.ac.za/rds](http://www.sun.ac.za/rds)) should be submitted to the Committee before the year has expired. The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected randomly and subjected to an external audit.

Translations of the consent document in the languages applicable to the study participants should be submitted.

Federal Wide Assurance Number: 00001372

Institutional Review Board (IRB) Number: IRB0005239

The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes 2004 (Department of Health).

19 October 2009 08:55

Page 1 of 2



Verbind tot Optimate Gesondheid - Committed to Optimal Health  
Afdeling Navorsingseontwikkeling en -steun - Division of Research Development and Support  
Postbus/FPO Box 19083 · Tygerberg 7505 · Suid-Afrika/South Africa  
Tel: +27 21 933 9075 · Fax/Fax: +27 21 931 3352

## Appendix 2



Verwyding  
Reference: 15/16/RP 114/2009

Balathiso

Navrae  
Enquiries  
Imibuzo

Telefoon  
Telephone

**Departement van Gesondheid  
Department of Health  
iSebe IzeMpilo**

Dear Dr

**RE: Drug interactions in primary healthcare in the George area, South Africa: A cross sectional study**

Thank you for submitting your proposal to undertake the above-mentioned study. We are pleased to inform you that the department has granted you approval for your research. Please contact the following members of staff to assist you with access to the facilities:

1. Dr Email: Tel No.:

Kindly ensure that the following are adhered to:

1. Arrangements can be made with managers, providing that normal activities at requested facilities are not interrupted.
2. Researchers, in accessing provincial health facilities, are expressing consent to provide the department with an electronic copy of the final report within six months of completion of research. This can be submitted to the provincial Research Co-ordinator.
3. The reference number above should be quoted in all future correspondence.

We look forward to hearing from you.

Yours sincerely

## References

1. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. *Ann Pharmacother* 2002;36(9):1331-6.
2. Begrnhøj L, Thirstrup S, Kristensen MB, Bjerrum L, Sonne J. Prevalence of inappropriate prescribing in primary care. *Pharm World Sci* 2007;29(3):109-15.
3. Linnarsson R. Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. *Scand J Prim Health Care* 1993;11(3):181-6.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. *JAMA* 1998;279(15):1200-05.
5. Novak PH, Ekins-Daukes S, Simpson CR, Milne RM, Helms P, McLay JS. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. *Br J Clin Pharmacol* 2005;59(6):712-7.
6. Bregnhøj L, Thirstrup S, Kristensen MB, Bjerrum L, Sonne J. Prevalence of inappropriate prescribing in primary care. *Pharm World Sci* 2007;29(3):109-15.
7. Doubova Dubova SV, Reyes-Morales H, Torres-Arreola Ldel P, Suárez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. *BMC Health Serv Res* 2007;7:147.
8. Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. *Scand J Prim Health Care* 2003;21(3):153-8.
9. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. *Drugs Aging*. 1998;12:485-94.
10. Hines L. Managing drug-drug interaction risks. <http://www.medscape.com>(Accessed last on 25 Feb 2009).
11. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. *J Am Acad Dermatol* 2002;47(4):467-84.

12. Hansten PD, Horn JR. The top 100 drug interactions. A guide to patient management. 2008 ed. Fowlerville (Michigan): H&H Publications; 2008.
13. Hansten PD, Horn JR. Drug Interactions Analysis and Management (DIAM). St. Louis (MO): Wolters Kluwer Health; 2008.
14. Shukla UA, Pittman KA, Barbhaya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. *J Clin Pharmacol* 1992;32(8):725-31.
15. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. *Br J Clin Pharmacol* 2004;57(2):121-6.
16. Beard SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. *J Am Pharm Assoc (Wash)* 2000;40(5):637-44.
17. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. *Drug Saf* 2005;28(1):67-80.
18. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. *Br J Clin Pharmacol* 2007;63(2):136-47.
19. Snaith A, Pugh L, Simpson CR, McLay JS. The potential for interaction between warfarin and coprescribed medication: a retrospective study in primary care. *Am J Cardiovasc Drugs* 2008;8(3):207-12.
20. Katende-Kyenda NL, Lubbe MS, Serfontein JH, Truter I. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa. *J Clin Pharm Ther* 2008;33(4):393-400.
21. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. *CMAJ* 1996;154(8):1177-84.
22. Fillit HM, Futterman R, Orland BI, Chim T, Susnow L, Picariello GP, et al. Polypharmacy management in Medicare managed care: changes in prescribing by

- primary care physicians resulting from a program promoting medication reviews. *Am J Manag Care* 1999;5(5):587-94.
23. Hogerzeil HV. Promoting rational prescribing: an international perspective. *Br J Clin Pharmacol* 1995;39(1):1-6.
  24. Young B. Medication reconciliation matters. *Medsurg Nurs* 2008;17(5):332-6.
  25. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. *Am J Health Syst Pharm* 1999;56(15):1524-9.
  26. Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. *QJM* 2007;100(11):691-7.
  27. Tamblyn R, Huang A, Taylor L, Kawasumi Y, Bartlett G, Grad R, et al. A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care. *J Am Med Inform Assoc* 2008;15(4):430-8.
  28. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. *Ann Intern Med* 1991;114:257-63.
  29. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1991;114:735-40.
  30. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. *Arch Intern Med* 1993;153:1665-70.
  31. Linnarsson R. Drug interactions in primary health care: A retrospective database study and its implications for the design of a computerized decision support system. *Scand J Prim Health Care* 1993;11(3):181-6.
  32. López-Picazo JJ, Ruiz JC, Sánchez JF, Ariza A, Aguilera B. A hazard scale for severe interactions: a tool for establishing prioritising strategies to improve the safety of the prescription in family medicine. *Aten Primaria* 2011 Jan 6. [Epub ahead of print].

33. Corona-Rojo JA, Altagracia-Martínez M, Kravzov-Jinich J, Vázquez-Cervantes L, Pérez-Montoya E, Rubio-Poo C. Potential prescription patterns and errors in elderly adult patients attending public primary health care centers in Mexico City. *Clin Interv Aging* 2009;4:343-50.
34. Snyder AM, Klinker K, Orrick JJ, Janelle J, Winterstein AG. An in-depth analysis of medication errors in hospitalized patients with HIV. *Ann Pharmacother* 2011;45(4):459-68.
35. Pavličević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDS in primary care: A controlled trial. *Can J Clin Pharmacol* 2008;15(3):e372-82.
36. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, et al. Systematic review: Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers for ischemic heart disease. *Ann Intern Med* 2009;151(12):861-71.
37. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. *J Am Coll Cardiol* 1992;20(7):1549-55.
38. Brunner-La Rocca HP. Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved? *Chest* 2003;124(4):1192-4.
39. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. *Clin Pharmacol Ther* 1992;52(5):479-86.
40. Dallenbach MF, Bovier PA, Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. *QJM* 2007;100(11):691-7.
41. Gaikwad R, Sketris I, Shepherd M, Duffy J. Evaluation of accuracy of drug interaction alerts triggered by two electronic medical record systems in primary healthcare. *Health Informatics J* 2007;13(3):163-77.